- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00622882
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultation for Better Outcomes From Staphylococcus Aureus Bacteremia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bacteremia is a serious manifestation of Staphylococcus aureus infection with an attributable mortality as high as 25% in MRSA bacteremia. More than a third of patients end up with complications such as endocarditis, osteomyelitis or pneumonia.
Overall the outcome of patients with respect to mortality or recurrence is better in patients who have an eradicable focus and have received an appropriate antibiotic dose and duration. Also complicated bacteremia is more common in patients with
- persistent bacteremia or fever
- prosthetic device
- new murmur
- skin findings of a systemic infection
Based on this evidence, an ID consultation could improve the outcomes of patients with SAB by
- Advising adequate antibiotic dosage and duration
- Sourcing out and counselling eradication of any focus of infection
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 11974
- Recruiting
- National University Hospital
-
Contact:
- Paul A Tambyah, Dip ABIM
- Phone Number: (65)67724375
- Email: mdcpat@nus.edu.sg
-
Principal Investigator:
- Paul A Tambyah, Dip ABIM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All inpatients at the National University Hospital with Staphylococcus aureus (both methicillin sensitive and methicillin resistant) bacteremia isolated within the defined time period
Exclusion Criteria:
- Patients who died or were discharged before the notification from the laboratory
- Neonates
- Polymicrobial bacteremia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ID
Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
|
Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
Other Names:
|
No Intervention: NO ID
Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
mortality
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
recurrence
Time Frame: 2 year
|
2 year
|
duration of hospitalisation
Time Frame: 1 year
|
1 year
|
financial costs of hospitalisation
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paul A Tambyah, MD, National University, Singapore
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSRB-B/06/274
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus Bacteremia
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Todd C. Lee MD MPH FIDSANot yet recruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | Staphylococcal SepsisCanada
-
ContraFectCompletedStaphylococcus Aureus Bacteremia | Staphylococcus Aureus EndocarditisUnited States, Belgium, Bulgaria, Chile, Czechia, France, Germany, Greece, Guatemala, Israel, Italy, Russian Federation, Spain, United Kingdom
-
University of PennsylvaniaWithdrawnStaphylococcus Aureus Bacteremia | Staphylococcus Aureus EndocarditisUnited States
-
Thomas BenfieldUnknownStaphylococcus Aureus BacteremiaDenmark
-
Bristol-Myers SquibbCompleted
-
University Medicine GreifswaldRecruitingStaphylococcus Aureus BacteremiaGermany
-
University of MelbourneRadboud University Medical Center; Sunnybrook Health Sciences Centre; UMC Utrecht and other collaboratorsRecruitingStaphylococcus Aureus BacteremiaAustralia, New Zealand, Canada, Singapore, Netherlands, Israel
-
Clinical Research Centre, MalaysiaNot yet recruitingStaphylococcus Aureus BacteremiaMalaysia
Clinical Trials on infectious disease specialist consultation
-
Henri Mondor University HospitalCompletedPatients Under Antimicrobial TherapyFrance
-
Henri Mondor University HospitalCompletedPatients Receiving Antimicrobial TherapyFrance
-
US Department of Veterans AffairsCompleted
-
University Hospital, Clermont-FerrandRecruiting
-
The Third Xiangya Hospital of Central South UniversitySANSURE BIOTECH INC.UnknownInfectious Disease ScreeningChina
-
University of PittsburghRecruitingGender Dysphoria | TransgenderUnited States
-
The University of Texas Health Science Center,...Not yet recruitingAnemia | Decreased Glomerular Filtration RateUnited States
-
Universiteit AntwerpenVitazRecruiting
-
Assistance Publique Hopitaux De MarseilleUnknownCardiovascular Consequences After an Episode of COVID 19France
-
University of PittsburghRecruitingAutoimmune Diseases | CancerUnited States